TACTILE SYSTEMS TECHNOLOGY INC (TCMD)
NASDAQ · Instruments & Medical Devices · Surgical & Medical Instruments & Apparatus
- Price
- $22.43
- Day
- -1.10%
- Market cap
- $508.09M
- P/E
- 20.4
Close 2026-09-23.
The company
Overview Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. and in September 2013, we began doing business as “Tactile Medical”. Our mission is to help people suffering from chronic diseases live better and care for themselves at home. We focus our efforts on advancing the standard of care in treating underserved chronic diseases in the home to improve patient outcomes and quality of life and help control rising healthcare expenditures. Our areas of therapeutic focus are (1) vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency, (2) oncology, where lymphedema is a common consequence among cancer survivors and (3) providing airway clearance therapy for those suffering from chronic respiratory conditions. We possess a unique, scalable platform to deliver at-home healthcare solutions throughout the United States. This evolving home care delivery model is recognized by policymakers and insurance payers as a key for controlling rising healthcare costs.
From Item 1: Overview.
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- CADIAN CAPITAL MANAGEMENT, LP — $46.96M
- DIMENSIONAL FUND ADVISORS LP — $30.89M
- VANGUARD CAPITAL MANAGEMENT LLC — $28.89M
- BlackRock, Inc. — $28.66M
- Driehaus Capital Management LLC — $27.93M
- MORGAN STANLEY — $23.32M
- BlackRock, Inc. — $21.04M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $21.04M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Dodd Sheri Louise (Chief Executive Officer) sold 10,978 shares at $29.44 on 2026-08-10
- Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER) sold 4,631 shares at $24.49 on 2026-05-11
- Dodd Sheri Louise (Chief Executive Officer) sold 10,993 shares at $28.94 on 2026-02-24
- Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER) sold 7,701 shares at $28.94 on 2026-02-24
- Burns Kristie (Sr. VP Mktg & Clinical Affairs) sold 6,246 shares at $28.94 on 2026-02-24
- Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER) sold 5,322 shares at $28.28 on 2026-02-23
Recent filings
- 144 — 2026-08-20
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G/A — 2026-08-12
- 4 — 2026-08-12
- 144 — 2026-08-10
- 10-Q — 2026-08-10
- 8-K — 2026-08-10
- 8-K — 2026-07-13
- 4 — 2026-05-13
- 144 — 2026-05-11